Biophytis SA logo
Biophytis SA BPTS

Annual report 2023
added 12-27-2025

report update icon

Biophytis SA Cash Flow 2011-2026 | BPTS

Annual Cash Flow Biophytis SA

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

- - -23.8 M -9.74 M -15.1 M -12.1 M - - - - - - -

All numbers in EUR currency

Quarterly Cash Flow Biophytis SA

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

All numbers in EUR currency

Cash Flow Statement is one of the three key financial reports of the company Biophytis SA, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 18.46 -0.22 % $ 2.72 B usaUSA
Amgen Amgen
AMGN
$ 344.63 0.8 % $ 185 B usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 70.06 1.05 % $ 9.37 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Biogen Biogen
BIIB
$ 179.46 -0.24 % $ 26.1 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.7 3.85 % $ 17 M usaUSA
Adagene Adagene
ADAG
$ 2.6 -5.45 % $ 146 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Burford Capital Limited Burford Capital Limited
BUR
$ 9.78 0.93 % $ 1.57 B britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.14 -0.95 % $ 7.55 B australiaAustralia
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.32 7.67 % $ 9.4 B israelIsrael
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Compugen Ltd. Compugen Ltd.
CGEN
$ 1.83 -0.3 % $ 164 M israelIsrael
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.41 - $ 264 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 24.98 1.54 % $ 1.61 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 226.97 0.38 % $ 5 B danmarkDanmark
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 3.86 1.72 % $ 116 M franceFrance
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 109.35 -3.87 % $ 27.2 B germanyGermany
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.38 0.73 % $ 352 M britainBritain
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 42.1 5.59 % $ 4.35 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 24.77 1.93 % $ 2.93 B usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.7 -3.14 % $ 81 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 13.96 2.01 % $ 4.31 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 6.58 - $ 1.36 B usaUSA